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Intellectual disability (ID) is the unavoidable hallmark of Down syndrome (DS), with a
heavy impact on public health. Accumulating evidence shows that DS is characterized by
numerous neurodevelopmental alterations among which the reduction of neurogenesis,
dendritic hypotrophy and connectivity alterations appear to play a particularly prominent
role. Although the mechanisms whereby gene triplication impairs brain development in
DS have not been fully clarified, it is theoretically possible to correct trisomy-dependent
defects with targeted pharmacotherapies. This review summarizes what we know about
the effects of pharmacotherapies during different life stages in mouse models of DS.
Since brain alterations in DS start to be present prenatally, the prenatal period represents
an optimum window of opportunity for therapeutic interventions. Importantly, recent
studies clearly show that treatment during the prenatal period can rescue overall brain
development and behavior and that this effect outlasts treatment cessation. Although late
therapies are unlikely to exert drastic changes in the brain, they may have an impact on
the hippocampus, a brain region where neurogenesis continues throughout life. Indeed,
treatment at adult life stages improves or even rescues hippocampal neurogenesis and
connectivity and hippocampal-dependent learning and memory, although the duration
of these effects still remains, in the majority of cases, a matter of investigation. The
exciting discovery that trisomy-linked brain abnormalities can be prevented with early
interventions gives us reason to believe that treatments during pregnancy may rescue
brain development in fetuses with DS. For this reason we deem it extremely important to
expedite the discovery of additional therapies practicable in humans in order to identify
the best treatment/s in terms of efficacy and paucity of side effects. Prompt achievement
of this goal is the big challenge for the scientific community of researchers interested
in DS.
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Intellectual disability (ID) is the most serious problem of Down syndrome (DS), with a heavy
impact on families and society. Intense eﬀorts of scientists worldwide are currently trying to
discover interventions that improve or even rescue ID inDS. The results summarized below suggest
that therapy for DS may be possible and that appropriately timed therapies may have a large impact
on ID. This achievement would give children with DS the opportunity of a normal and autonomous
life, alleviate the psychological burden on their families and solve a public health problem. This
review summarizes therapies attempted in mouse models of DS, focusing in particular on early
interventions.
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DS is Characterized by Brain Defects that
can be Traced Back to Fetal Life Stages
IQ in people with DS usually falls in the moderately to severely
retarded range (IQ = 25–55) and mental age is rarely over
8 years (See Rachidi and Lopes, 2008; Dierssen, 2012). The
IQ in DS is not constant during life but decreases with age
and an early deceleration occurs between the age of 6 months
and 2 years, with a further decline in adolescents. Children
with DS exhibit incomplete and delayed acquisition of motor,
linguistic, cognitive, and adaptive functions, compared with
developing children of the same mental age. The brain of a
child with DS develops diﬀerently from a normal brain and
attains a form that is reduced in size and altered in shape.
Widespread neurogenesis impairment has been documented
in fetuses with DS (Contestabile et al., 2007; Guidi et al.,
2008, 2011) and in mouse models of DS (Chakrabarti et al.,
2007; Bianchi et al., 2010a,b; Trazzi et al., 2011) during
critical brain developmental stages and is one of the major
determinants of ID in DS. Proliferation impairment is worsened
by a reduction in the acquisition of a neuronal phenotype
and a relative increase in astrogliogenesis. In contrast, there
is an increase in the production of inhibitory neurons that
causes an excitation/inhibition imbalance (Chakrabarti et al.,
2010). In addition to neurogenesis impairment, the DS brain is
characterized by dendritic hypotrophy, spine density reduction,
and alterations in spine shape (Takashima et al., 1989; Becker
et al., 1991; Belichenko et al., 2004; Benavides-Piccione et al.,
2004; Guidi et al., 2013) and widespread alterations of various
transmitter and receptor systems (see Bartesaghi et al., 2011).
These defects, which imply altered network formation and
functioning, are also important determinants of ID in DS.
The Ts65Dn Mouse: A Widely Used Model
for Studying DS
Various mouse models have been created that are trisomic
for diﬀerent sets of genes of Hsa21. Animal models do not
reproduce the human disease with all its complexities but rather
model speciﬁc aspects of the disease and no perfect model of
DS exists. The Ts65Dn mouse is the most studied and best
characterized model of DS. It bears segmental trisomy for a
distal region of Mmu16 that contains approximately 55% of
Hsa21 conserved genes (Davisson et al., 1990). This model is
additionally trisomic for approximately 50 genes that are non-
hortologous to Hsa21 (Rueda et al., 2012). During the past 20
years, numerous studies have demonstrated common features
between Ts65Dn and humans, and the Ts65Dn mouse is, at the
moment, the only model of DS used in pre-clinical studies to
develop therapies for DS (Gardiner, 2015). However, there are
some aspects that make this model limited. (1) The Ts65Dn
mouse lacks numerous Hsa21 orthologous genes and has some
Mmu17 genes that are non-trisomic in humans. These genes may
confound results of therapeutic interventions. (2) Since males
are sterile, mice are generated from Ts65Dn dams. The trisomic
condition of mothers could cause developmental problems of
the pups independently from trisomy. Along the same line of
reasoning, embryonic treatments may have beneﬁcial eﬀects on
trisomic pups that are secondary to the beneﬁcial eﬀects on the
trisomic dams. Due to these limitations, treatment on Ts65Dn
mice may have an unpredictable clinical outcome. Nevertheless,
the Ts65Dn mouse has allowed scientists to discover treatments
that may also be beneﬁcial in individuals with DS.
Brain Functions in DS can be
Pharmacologically Improved
The mechanisms whereby gene triplication leads to brain
developmental alteration and, hence, ID remain to be elucidated.
Among the triplicated genes DYRK1A, SIM2, DSCAM, GIRK2,
Olig1, and Olig2, SYNJ1, and APP are thought to be heavily
involved in the DS neurological phenotype. Moreover, APP
triplication appears to be a key factor that favors the almost
unavoidable development of Alzheimer’s disease in adults
with DS. Ideally, identiﬁcation of the molecular mechanisms
underlying brain abnormalities in DS will provide a rational
basis from which to devise therapies that, by targeting speciﬁc
cellular pathway/s, may correct the developmental defects of
the DS brain. Although the molecular mechanisms that disrupt
brain development in DS have not been fully clariﬁed so far,
various therapies have been attempted during the past few years
in the Ts65Dn mouse model showing that it is possible to
pharmacologically improve cognitive performance and diﬀerent
aspects of the DS brain phenotype (Tables 1, 2).
The Number of Pre-clinical Studies for DS
has Progressively Increased during the
Past Few Years
During the past 14 years the number of studies focusing on
pharmacotherapies for DS has grown almost exponentially. The
results of a Medline research [a group of keywords was: “Down
syndrome AND mouse model AND (therapy OR treatment OR
restoration OR rescue OR improvement)”; a second group of
keywords was: “Down syndrome ANDmouse model AND LTP”]
are summarized in Figure 1. Figure 1A summarizes the number
of articles published since 2002 up to the beginning of current
year. While in the period 2002–2008 the overall number of
articles was 15 (Figure 1B), with a mean number of two articles
per year, in the period 2009–2015 the overall number of articles
was 40 (Figure 1B), with a mean number of six articles per year.
These ﬁgures are quite encouraging because they show that the
relatively small community of researchers interested in DS is
making increasing eﬀorts to ﬁnd treatment for DS. This gives us
hope that this intense commitment will produce good results in a
near future.
Numerous Therapies Have Been
Attempted in Order to Improve the
Phenotype of the Trisomic Brain
A number of therapies have been tested so far in mouse models
of DS in order to improve the DS-linked brain phenotype.
Since most of these therapies have been tested in the Ts65Dn
mouse, the most popular model of DS, we will focus here mainly
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on therapies tested in this model. These therapies, which have
been selected according to diﬀerent rationales, can be variously
classiﬁed, according to the chosen common denominators. Here
we have grouped the attempted therapies into ﬁve major classes,
named A–E (also reported in Tables 1, 2). (A) Therapies targeted
to transmitter systems. (i) Therapies enhancing cholinergic
trasmission in order to counteract age-related damage of the
cholinergic systems; (ii) Therapies antagonizing GABAergic
transmission, in order to reduce excessive inhibition; (iii)
Therapies enhancing noradrenergic transmission, in order to
compensate for dysfunctions of noradrenergic aﬀerents to
the hippocampus; (iv) Therapies targeted to the glutamate
NMDA receptor, in order to restore its function; (v) Therapies
targeted to the serotonergic system, in order to enhance
defective serotonergic signaling; (vi) Therapies targeted to the
endocannabinoid system, in order to increase its activity. (B)
Therapies employing neuroprotective agents, antioxidants, and
free radical scavengers, in order to reduce neurodegeneration,
a typical feature of the DS brain. (C) Therapies targeted to
perturbed signaling pathways. (D) Therapies to normalize the
expression of proteins coded by triplicated genes. (E) Therapies
that are known to have a proneurogenic eﬀect.
The total number of studies for each of these ﬁve classes is
shown in Figure 2A. It is evident that more than one half of the
studies (32 out of a total of 55) that have attempted to rescue
DS brain phenotypes have used drugs that act on transmitter
systems. Many transmitter systems are altered in DS and by
correcting altered synaptic function it may be possible to reinstate
signal transfer, on one hand, and activity-dependent cellular
functions, on the other. Most of the studies belonging to class A
focus on the GABAergic system (Figure 2B). The rationale is that
since an excessive inhibition characterizes the trisomic brain, it
may be possible to normalize its function by reducing inhibition.
The second most numerous group of therapies belongs to class
B. This class may expand if we shift therapies targeted to the
cholinergic system from class A to class B. The rationale for
the wide use of neuroprotective agents or antioxidants depends
on the fact that the trisomic brain undergoes neurodegeneration
and develops an Alzheimer’s-like pathology with age. Thus,
neuroprotective agents may prevent or delay neurodegeneration.
Of course, the classiﬁcation criteria are not entirely ﬂaw-free
and categories may be overlapping. For instance, therapies
acting on the cholinergic system may belong to class A of this
review as well as to class B. The outcomes of therapies of the
diﬀerent classes can be found in Tables 1, 2. Note that this
review reports results of pharmacological interventions that have
examined one or more of these phenotypic features: learning and
memory, LTP, neurogenesis/cellularity, dendritic pattern, and
neurodegeneration. Therapies based on non-pharmacological
approaches have not been included.
Trisomy-linked Brain Phenotypes can be
Rescued by Different Therapies
By looking at Tables 1, 2 it appears that a variety of diﬀerent
agents, that act on diﬀerent targets, can rescue one or more of
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FIGURE 1 | Number of studies focused on pharmacotherapies in Down
syndrome mouse models in the period 2002–2015. (A) Number or studies
per year. (B) Cumulative number of studies in the period 2002–2008 and
2009–2015.
the DS brain phenotypes. For instance, memory can be improved
by antagonizing GABA receptors (Table 1) or by antagonizing
the NMDA receptor (Table 1); neurogenesis can be increased
by drugs that interact with GSK3β, such as lithium (Table 1),
or drugs that interact with the serotonergic system, such as
ﬂuoxetine (Tables 1, 2). The outcomes of the studies reported
in Table 1 are summarized in Figure 3A. Importantly, 36 out
of 58 interventions obtained the full rescue of the examined
phenotype (Figure 3A, Rescued); 11 interventions obtained
an improvement (Figure 3A, Improved); four interventions
obtained the rescue of some of the examined phenotypes but not
others (Figure 3A, Failed/Rescued); and only seven interventions
were ineﬀective (Figure 3A, Failed). It must be observed that
the studies reported in Table 1 used mice of diﬀerent ages and
treatments with diﬀerent durations. Thus, it cannot be ruled out
that the ineﬀectiveness of some treatments may be related to
the age of mice and/or to an insuﬃcient treatment duration. In
addition, it must be emphasized that the results of treatment
(“rescue,” “improvement” and “failure”) reported in the column
“Outcome” of Table 1 refer to the speciﬁc phenotype indicated
in the ﬁrst column. We must be aware that the rescue of a
given phenotypic feature may not necessarily lead to a cognitive
improvement. Although we take these limitations into account,
if we group together interventions that elicit a rescue or an
improvement of the observed phenotype/s it ensures that 51 out
of 58 interventions (88%) have a positive impact on the DS brain.
We believe that this is an extremely important success that may
give new hope for DS.
The question now arises as to how widely diﬀerent approaches
may produce the same result. It should be observed that the
gene burden in DS alters numerous cellular pathways. Diﬀerent
signaling pathways concur, in many cases, to regulate the
same cellular process. Thus, pharmacological restoration of a
single pathway may be suﬃcient to correct a given defect.
Consequently, therapies interacting with diﬀerent pathways may
ultimately lead to similar results. This aspect should not be
disregarded, because the possibility to have a panel of eﬀective
therapies at hand will give us the opportunity to select the agent
with as few side eﬀects as possible.
Although animal models are essential for translation of drug
ﬁndings from bench to bedside, we must be aware of possible
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FIGURE 2 | Pharmacotherapies used in the Ts65Dn mouse models of
Down syndrome grouped per class. (A) Pharmacotherapies grouped into
five classes (A–E), as explained in the text. The histogram shows the number
of published studies for each class. (B) Number of studies for each subclass
of pharmacotherapies belonging to class A (see text for explanation).
Abbreviations: Cann Sys, cannabinoid sysem; Chol Sys, cholinegic system;
GABA Sys, GABAergic system; Glut Sys, glutamatergic system; NA Sys,
noradrenergic system; Ser Sys, serotonergic system.
limitations of the treatments attempted inmousemodels in terms
of translational value. The best validated animal model is not able
to yield conclusive data when the experimental design is ﬂawed or
the execution of the study is not well-controlled. Yet, the studies
reported in Tables 1, 2were (a) conducted on the Ts65Dnmouse,
which in spite of some limitations replicates many aspects of
the human disease, and (b) targeted to molecular alterations or
phenotypic features present in the model and in the DS brain.
These studies may provide, therefore, a good starting point that,
after better characterization of dosing, timing, and absence of
short- and long-term side eﬀects may help in the design of future
clinical trials.
Is there an Optimum Timing of Therapies
for DS?
Most of the attempts to pharmacologically improve trisomy-
linked brain alterations have been made in adult mice (compare
FIGURE 3 | Pharmacotherapies in the Ts65Dn mouse model of Down
syndrome. (A) The histogram shows the number of attempted
pharmacotherapies in the Ts65Dn mouse model of DS that rescued (Rescued),
improved (Improved), partially rescued (Failed/Rescued) the examined
phenotype/s or had no effect (Failed). Data derive from Tables 1, 2. (B) The
histogram shows the number of studies in which pharmacotherapies were
administered at adult life stages, in the neonatal period and in the prenatal (in
some instances plus post-natal) period. Data derive from Tables 1, 2.
Tables 1, 2). Figure 3B summarizes the number of studies
in the Ts65Dn mouse models of DS that have tested the
eﬀects of pharmacotherapies at adult life stages, during the
neonatal period, and during the embryonic period. Therapies
were administered at adult life stages in 38 out of 55 studies
(69%), in the neonatal period in eight studies (15%) and in
the prenatal or prenatal + neonatal period in nine studies
(16%). This striking imbalance deserves a comment. As hinted
above, neurodevelopmental defects in people with DS (and
mouse models of DS) are already present at fetal life stages.
This is the period in which the bulk of neurogenesis takes
place (Figure 4). There are two important exceptions to this
rule: the hippocampal dentate gyrus and the cerebellum, two
regions where granule neuron production largely occurs in the
very early post-natal period. While in the hippocampal dentate
gyrus neurogenesis goes on (at a slow rate) throughout life,
in the cerebellum neurogenesis stops shortly after the early
post-natal period (Figure 4). In view of the time course of
brain development we can envisage that: (i) adult therapies
may modulate ongoing hippocampal neurogenesis and, possibly,
already existing hippocampal and extrahippocampal circuits. In
addition, adult therapies may be used in order to prevent AD-
linked neurodegeneration; (ii) neonatal therapies may largely
shape hippocampal and cerebellar development; (iii) prenatal
therapies may have by far the largest impact, by potentially
aﬀecting development of the whole brain (Figure 4). Therefore,
we can expect that, while late therapies may modify the trisomic
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FIGURE 4 | Schematic representation of the timeline of brain
development. Timeline of mouse (A) and human (B) brain development. See
text for explanations. The dotted arrows indicate a reduction in the rate of
neurogenesis. The double-headed red arrows delineate the period of
maximum neurogenesis in the different brain regions of the mouse and human
brain. Abbreviations: CB, cerebellum; CX, neocortex; DG, dentate gyrys; E,
embryonic; F, fetal; M, month; P, post-natal; W, week.
brain to a relatively limited extent, perinatal therapies are likely
to exert more widespread eﬀects, potentially aﬀecting overall
brain development. In the following sections we will summarize
what we currently know about the eﬃcacy of pharmacotherapies
during diﬀerent life stages in the Ts65Dn mouse model of DS.
However, since this review intends to focus on the impact of
early therapies, the eﬀects of therapies at later life stages will
only be brieﬂy mentioned. For more details, the reader may
refer to excellent recent reviews (Costa and Scott-McKean, 2013;
Gardiner, 2015).
Adult Therapies
As mentioned above, most of the studies that have sought to
pharmacologically improve the DS brain phenotype have mainly
used adult mice. These studies focused on the hippocampus
because hippocampal-dependent learning and memory are
severely aﬀected in DS. Table 1 summarizes the results of
studies in adult mouse models of DS obtained during the past
14 years. Results of diﬀerent therapies are grouped by the
phenotypic features that have been examined. Since, in many
instances, more than one feature has been taken into account
in the same study, that study may appear more than once. The
advantage of reporting results in this way is that i) the impact
of diﬀerent therapies on the same phenotypic feature and ii)
the number of studies that have focused on that feature can
be readily appreciated. Most of the studies on adult mice have
examined the eﬀect of treatment on learning and memory (L/M),
without trying to ﬁnd a mechanistic link between the behavioral
eﬀects and changes in the architecture and/or physiology of the
hippocampal circuits. A few studies have examined, in addition
to L/M, long-term potentiation (LTP) at hippocampal synapses,
a form of synaptic plasticity that has been classically considered
to be the electrophysiological correlate of learning and memory,
although this view is becoming questionable (Abbas et al., 2015).
Granule neurons of the hippocampal dentate gyrus continue
to proliferate across life. The adult-produced granule neurons
integrate into the hippocampal circuits and appear to play a
role in memory performance (Imayoshi et al., 2008). However,
relatively few studies have examined the eﬀect of treatment on
hippocampal neurogenesis. Signal processing depends on proper
connectivity and thus, it is important to examine the eﬀect of
treatment on dendritic architecture and connectivity. However,
there is a striking lack of information regarding this issue. A
study in TgDyrk1A mice shows that EGCG restores, in addition
to neurogenesis, granule cell dendritic architecture (Pons-Espinal
et al., 2013) but, to our knowledge, only a single study has
examined the eﬀect of treatment on dendritic architecture in
the Ts65Dn mouse (Table 1). The Ts65Dn mouse, similarly to
individuals with DS, is bound to develop AD with age. Thus,
it is of relevance to establish whether AD-like pathology can
be pharmacologically improved. Accordingly, some studies have
addressed this issue by speciﬁcally examining neurodegeneration
(Table 1).
The lack of a common experimental protocol across the
diﬀerent research groups makes it diﬃcult to compare the
eﬃcacy of diﬀerent treatments. For instance, experiments vary
for factors such as age of mice, doses, duration of treatment
(acute/chronic) and experimental design. In addition, a limited
number of trisomy-linked phenotypes were examined by most
of these studies. Thus, the eﬀect of treatment on the non-
examined features remains to be established. Yet, by examining
Table 1, it appears that 19 out of 36 interventions (53%)
that examined L/M caused rescue of L/M, 7 (19%) caused
an improvement and 10 (28%) had no eﬀect; 10 out of 11
interventions that examined LTP caused rescue of LTP and
one intervention caused an improvement; six out of eight
interventions that examined neurogenesis caused restoration of
neurogenesis. Thus, there is a large panel of treatments that is
eﬀective in rescuing/improving the major defects of the trisomic
brain, at least in the Ts65Dn mouse model, although the clinical
signiﬁcance of acute treatments (see Table 1) remains to be
established. A critical aspect that has been largely neglected
is whether the eﬀects of treatment outlast treatment cessation.
Only six studies have taken this important issue into account
and while two of them show that the eﬀect of the selected
therapy outlasts treatment cessation, the remaining four give
disappointing results by showing that the eﬀects disappear with
time. The fact that the impact of a given therapy is ephemeral
should not be disregarded, because continuous administration of
drugs would be needed in order to maintain their eﬀects, which
might be impracticable.
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Future Directions for Adult Therapies in DS
The studies summarized in Table 1 are promising in that they
provide proof of principle demonstration that therapies can be
attempted in adults with DS in order to improve learning and
memory. Importantly, some of these studies have prompted
clinical trials in individuals with DS (Table 3). Following the
“pioneer” studies carried out so far, we believe that the issue of
adult therapies in mouse models of DS should be readdressed in
a more systematic manner in order to obtain pre-clinical results
with a translational impact. (1) Druggable candidate molecules
should be chosen. (2) Dosage and duration of treatment should
be carefully established in order to avoid toxic eﬀects. (3)
Treatments should be administered at diﬀerent times during
adulthood, in order to establish whether their eﬀect is age-
dependent. (4) The eﬀects of treatment should be examined
at both the neuroanatomical and functional level, in order
to establish the mechanism/s whereby a given therapy exerts
its eﬀects. (5) Evaluation of the eﬀects of treatment should
not be conﬁned to the hippocampus but also extend to other
brain regions, because changes in the synaptic organization
of other brain structures may contribute to the beneﬁcial
eﬀect of treatment. (6) Behavioral tests should be standardized.
(7) The eﬀects of a treatment should be examined after its
discontinuation, in order to establish whether it leaves an
enduring trace in the brain.
Early Therapies
Investigations into early therapies for DS are much less abundant
in comparison with the numerous studies regarding adult
therapies (see Figure 3B). However, the few available studies
show that perinatal therapies have impressive eﬀects on the
TABLE 3 | Clinical trials for intellectual disability in individuals with Down syndrome.
“A Study of RG1662 in Adults and Adolescents With Down Syndrome (CLEMATIS)” (ClinicalTrials.gov Identifier: NCT02024789)
https://clinicaltrials.gov/ct2/show/NCT02024789
“A Study of RG1662 in Individuals With Down Syndrome” (ClinicalTrials.gov Identifier: NCT01436955)
https://ClinicalTrials.gov/show/NCT01436955
“Down Syndrome Memantine Follow-up Study” (ClinicalTrials.gov Identifier: NCT02304302)
https://clinicaltrials.gov/ct2/show/NCT02304302?cond=%22Down+Syndrome%22&rank=40
“Efficacy and Safety of Memantine Hydrochloride in Enhancing the Cognitive Abilities of Young Adults With Down Syndrome” (ClinicalTrials.gov Identifier:
NCT01112683)
https://ClinicalTrials.gov/show/NCT01112683
“Memantine and Down’s Syndrome” (ClinicalTrials.gov Identifier: NCT00240760)
https://ClinicalTrials.gov/show/NCT00240760
“Down Syndrome Memantine Follow-up Study” (ClinicalTrials.gov Identifier: NCT02304302)
https://ClinicalTrials.gov/show/NCT02304302
“Evaluating The Safety Of Donepezil Hydrochloride (Aricept) For Up To 1 Year In The Treatment Of The Cognitive Dysfunction Exhibited By Children With
Down Syndrome—Follow-Up To A 10-Week, Double-Blind, Placebo-Controlled Trial” (ClinicalTrials.gov Identifier:NCT00675025).
https://clinicaltrials.gov/ct2/show/record/NCT00675025?term=%22down+syndrome%22+AND+%22clinical+trial%22&rank=4
“Evaluating The Efficacy And Safety Of Donepezil Hydrochloride (Aricept) In The Treatment Of The Cognitive Dysfunction Exhibited By Children With
Down Syndrome, Aged 6 To 10” (ClinicalTrials.gov Identifier: NCT00754013)
https://ClinicalTrials.gov/show/NCT00754013
“Evaluating The Efficacy And Safety Of Donepezil Hydrochloride (Aricept) In Treating Cognitive Dysfunction Exhibited By Children With Down Syndrome”
(ClinicalTrials.gov Identifier: NCT00570128)
https://ClinicalTrials.gov/show/NCT00570128
“Rivastigmine Study in Adolescents With Down Syndrome (DS-Riv)” (ClinicalTrials.gov Identifier: NCT01084135)
https://clinicaltrials.gov/ct2/show/NCT01084135?term=down+syndrome&rank=35
“Efficacy of Rivastigmine in Patients With Down Syndrome” (ClinicalTrials.gov Identifier: NCT00748007)
https://ClinicalTrials.gov/show/NCT00748007
“Egcg, a dyrk1a Inhibitor as Therapeutic Tool for Reversing Cognitive Deficits in Down Syndrome Individuals” (ClinicalTrials.gov Identifier: NCT01394796)
https://clinicaltrials.gov/ct2/show/NCT01394796
“Normalization of dyrk1A and APP Function as an Approach to Improve Cognitive Performance and Decelerate AD Progression in DS Subjects:
Epigallocatechin Gallate as Therapeutic Tool” (ClinicalTrials.gov Identifier: NCT01699711)
https://ClinicalTrials.gov/show/NCT01699711
“Vitamin E in Aging Persons With Down Syndrome” (ClinicalTrials.gov Identifier: NCT00056329)
https://clinicaltrials.gov/ct2/show/NCT00056329
“Multicenter Vitamin E Trial in Aging Persons With Down Syndrome” (ClinicalTrials.gov Identifier: NCT01594346)
https://ClinicalTrials.gov/show/NCT01594346
The clinical trials reported investigate the efficacy of RG1662 (a GABAAα5 negative allosteric modulator), memantine (antagonist of the NMDA receptor), Donepezil (AChE inhibitor),
Rivastigmine (AChE inhibitor), EGCG (Inhibitor of DYRK1A kinase), and Vitamin E (Antioxidant) on cognitive performance in children or adults with Down syndrome.
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trisomic brain and that they can rescue numerous trisomy-linked
brain alterations such as neurogenesis, brain cellularity, dendritic
development, connectivity, and behavior.
Neonatal Therapies
Table 2 shows that the three treatments that have been used so
far in neonate Ts65Dn mice (SAG, ﬂuoxetine, and EGCG) have
a positive impact on development of the cerebellum (SAG) and
hippocampus (ﬂuoxetine and EGCG).
SAG
The cerebellum is disproportionately small in the Ts65Dn mouse
and in individuals with DS and has a reduced number of granule
neurons and Purkinje cells. A ﬁrst pioneer study examined the
eﬀect of SAG, a synthetic activator of the Sonic hedgehog (Shh)
pathway, on cerebellar neurogenesis in newborn mice (Roper
et al., 2006). In rodents, most cerebellar granule neurons are
produced within the ﬁrst two post-natal weeks, with a peak
within the ﬁrst few post-natal days (Sillitoe and Joyner, 2007;
Sudarov and Joyner, 2007). Trisomic granule cell precursors
show a reduced response to the Sonic hedgehog protein signal
in vitro (Roper et al., 2006), demonstrating that this is a cell-
autonomous deﬁcit. In trisomic mice a single systemic treatment
with SAG at birth was found to increase neurogenesis and
restore granule cell precursor populations when mice were tested
at 6 days old (Roper et al., 2006). These are the ﬁrst results
demonstrating that an early therapy can fully reinstate defective
generation of cerebellar granule neurons. A subsequent study
showed that the eﬀect of a single neonatal injection of SAG
resulted in normal cerebellar morphology in tests carried out
when mice reached 4 months of age (Das et al., 2013). In
contrast, 6 days after a single neonatal injection of SAG, there
was no improvement in the dentate gyrus proliferation deﬁcit
in Ts65Dn mice (Das et al., 2013), suggesting that SAG may
diﬀerentially aﬀect diﬀerent neural precursor cell populations.
Yet, neonatal treatment with SAG restored performance in a
hippocampal-dependent task (MWM) and LTP at the synapse
Schaﬀer collaterals-CA1whenmice were 4months old (Das et al.,
2013). This evidence suggests that Shh has a role, that remains to
be deﬁned, in perinatal hippocampal development, and indicates
a long-lasting eﬀect of treatment on hippocampal function,
apparently independently from neurogenesis normalization. In
a more recent study, newborn mice received a single injection
of SAG and were examined at 4 months of age for cerebellum-
dependent learning (Gutierrez-Castellanos et al., 2013). Despite
the positive impact of SAG on cerebellar neuroanatomical
architecture, SAG treatment failed to rescue long-term cerebellar-
based learning in mice aged 4 months. The lack of eﬀect
may be attributable to the persistence of altered granule cell
electrophysiological properties and to the fact that in Ts65Dn
mice there are fewer Purkinje cells, the proliferation of which
cannot be aﬀected by treatment in view of their embryonic birth
date (Sillitoe and Joyner, 2007; Sudarov and Joyner, 2007).
Fluoxetine
The hippocampus of Ts65Dn mice and individuals with DS
is reduced in size due to severe neurogenesis alterations and
dendritic hypotrophy. The serotonergic system, which is altered
in DS, plays a fundamental role in neurogenesis and dendritic
development and, similarly to humans with DS, Ts65Dn mice
exhibit reduced expression of the serotonin 5-HT1A receptor.
Therefore, we wondered whether neonatal treatment with
ﬂuoxetine, a selective serotonin reuptake inhibitor, was able to
rescue hippocampal neurodevelopmental alterations. We found
that, immediately after a brief neonatal treatment (from P3
to P15) with ﬂuoxetine, hippocampal neurogenesis, and total
granule cell number were fully normalized (Bianchi et al., 2010b).
Importantly, 1 month after treatment cessation, treated Ts65Dn
mice exhibited fully restored granule cell number, restoration
of granule cell dendritic pattern, hippocampal connectivity,
signal transfer from the granule cells to CA3, and hippocampal-
dependent memory function (Bianchi et al., 2010b; Guidi et al.,
2013; Stagni et al., 2013). In a subsequent study we examined the
eﬀects of neonatal treatment with ﬂuoxetine when mice reached
adulthood (3 months of age) and found that in neonatally-treated
Ts65Dn mice hippocampal cellularity, dendritic architecture,
spine density, and memory functions were still fully rescued
(Stagni et al., 2015). Moreover, we found that the increased
levels of the APP-derived βCTF peptide in adult Ts65Dn mice
were normalized following neonatal treatment with ﬂuoxetine.
This eﬀect was accompanied by restoration of endosomal
abnormalities, a βCTF-dependent feature of DS and AD. These
results show that not only does early treatment with ﬂuoxetine
enduringly restore cognitive impairment but it may also prevent
early signs of AD-like pathology.
EGCG
Among HSA21 genes known to inﬂuence brain development,
Dyrk1A is one of the potent candidate genes closely implicated in
the DS neurological phenotype. Transgenicmice that overexpress
Dyrk1A exhibit brain developmental defects and behavioral
alterations similar to those found in DS patients and in murine
models with partial MMU16 trisomies, such as the Ts65Dn
mouse, which carries extra copies of several genes, including
the Dyrk1A gene (De la Torre et al., 2014). These observations
suggest that therapeutic strategies, aimed to modulate DYRK1A
activity may also have a positive eﬀect in DS. EGCG is one
of the most speciﬁc inhibitors of DYRK1A kinase activity.
We are currently examining the eﬀect of epigallocatechin-3-
gallate (EGCG), the major catechin in green tea on hippocampal
development. This phytochemical may have fewer side eﬀects
in comparison with SAG or ﬂuoxetine. Our results show that
neonatal treatment with EGCG fully restores hippocampal
neurogenesis and cellularity (Stagni et al., 2014). The duration of
these eﬀects still remains to be elucidated.
Prenatal Therapies
Five diﬀerent types of prenatal therapies have been used so far
in DS mouse models, four of which have a positive eﬀect on
numerous neurodevelopmental alterations (Table 2).
Choline
Cholinergic neurons provide the primary source of acetylcholine,
a fundamental brain neurotransmitter. A common trait of
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DS and AD individuals and the Ts65Dn mouse model is
the degeneration of the Basal Forebrain Cholinergic Neurons
(BFCNs). This group of neurons is important for (i) explicit
memory function, subserved by projections from the medial
septal nucleus to the hippocampus and (ii) attention and
working memory, subserved by projections from the nucleus
basalis to the frontal cortex. In Ts65Dn mice degeneration
of the BFCNs begins at 6 months of age, and, similarly
to humans with DS and AD, continues during adulthood.
Based on the unavoidable degeneration of BFCNs in these
pathologies, a series of related studies (Moon et al., 2010;
Velazquez et al., 2013; Ash et al., 2014; Kelley et al., 2014)
considered the hypothesis that improvement of BFCNs may
prevent the defects related to their degeneration. Moon et al.
(2010) supplemented the diet of pregnant Ts65Dn females
with high concentrations (> 4.5-fold than normal) of choline,
beginning at E1 and continuing during lactation until the
pups were weaned at P21. This regimen had previously
been shown to have several beneﬁts on normal rodents: (i)
organizational improvement on BFC neuronal systems, ii)
enduring enhancement of cognitive functions (i.e., explicit
memory and attention), and iii) neuroprotection against neural
insults (see Moon et al., 2010). The eﬀect of treatment on
the progeny of Ts65Dn mothers supplemented with choline
was evaluated starting from when mice were 6 months of
age. Behavioral testing was then continued for the following
6 months (Moon et al., 2010). In order to establish whether
treatment improved cognitive performance, mice were tested
with a ﬁve-choice visual discrimination task. Results showed
that increasing maternal choline intake during pregnancy and
lactation signiﬁcantly ameliorates attentional functioning of the
trisomic oﬀspring, albeit not completely. In a subsequent work
(Velazquez et al., 2013) the same schedule of treatment as in
Moon et al.’s study was used, plus environmental enrichment,
and mice were examined when they were 13–17 months of
age. Choline supplementation was found to restore hippocampal
neurogenesis (evaluated with doublecortin immunostaining)
and hippocampal-dependent spatial cognition, tested with the
Radial Arm Water Maze. Two subsequent studies examined
the eﬀect of the same treatment on the BFCNs in mice aged
4.3–7.5 and 13–17 months (Ash et al., 2014; Kelley et al.,
2014). A reduction in the number of BFCNs was found
in the medial septum of Ts65Dn mice aged 13–17 months.
This defect was improved by treatment (Ash et al., 2014).
These ﬁndings indicate that embryonic/early post-natal choline
supplementation has eﬀects that extend to very advanced life
stages. Although the mechanisms by which prenatal/neonatal
supplementation of choline reinstates hippocampal neurogenesis
and functions in the Ts65Dn mouse remain to be elucidated,
some theories were formulated by Moon et al. (2010) and
Velazquez et al. (2013). It is possible that choline mediates
these beneﬁcial eﬀects, altering the DNA methylation status
(epigenetic eﬀects) or regulating the production of phospholipid
components of membranes. Although these theories are
suggestive, we know too little about the molecular mechanism
of choline in DS and further studies are needed to solve these
questions.
Fluoxetine
Since serotonin is essential for neurogenesis and dendritic
development (Faber and Haring, 1999; Whitaker-Azmitia, 2001),
we hypothesized that treatment with ﬂuoxetine during pregnancy
could rescue most of the neurodevelopmental alterations that
characterize the trisomic brain. We treated pregnant Ts65Dn
females from E10 to delivery with the aim of restoring the
bulk of neurogenesis. We found that untreated Ts65Dn pups
exhibited a severe neurogenesis reduction and hypocellularity
throughout the forebrain (subventricular zone, subgranular
zone, neocortex, striatum, thalamus, hypothalamus), midbrain
(mesencephalon) and hindbrain (cerebellum and pons). In
Ts65Dn mice embryonically-treated with ﬂuoxetine precursor
proliferation and cellularity were fully restored in all these
regions. Furthermore, embryonic treatment with ﬂuoxetine
restored the expression of the 5-HT1A receptor in the
subventricular zone and hippocampal regions of Ts65Dn mice
(Guidi et al., 2014). To verify whether prenatal treatment with
ﬂuoxetine had enduring eﬀects, we examined the oﬀspring of
treated and untreated mothers when mice reached 45 days of
age, i.e., at 1.5 months after treatment cessation. We found
that neural precursor proliferation was still restored in the
two major post-natal brain neurogenic niches (subventricular
zone and subgranular zone of the dentate gyrus) (Guidi et al.,
2014). In addition, in the hippocampal dentate gyrus the
typical reduction in neurogenesis and the relative increase in
astrogliogenesis were fully corrected indicating a long-term eﬀect
on the diﬀerentiation program. The total number of granule
neurons was also still restored. Furthermore, in embryonically-
treated Ts65Dn mice the dendritic development of post-natally
born granule neurons was normalized with full correction of
the severe dendritic hypotrophy that characterizes the trisomic
condition. The counterpart of this eﬀect was restoration of
pre- and post-synaptic terminals. Finally, embryonically- treated
Ts65Dn mice aged 45 days exhibited restoration of cognitive
performance, indicating that the positive impact of embryonic
treatment on brain development was functionally eﬀective in
adulthood.
NAP+SAL
Activity-dependent neuroprotective protein (ADNP) and
activity-dependent neurotrophic factor (ADNF) are essential
for brain formation (Incerti et al., 2011). The active peptide
fragments of these proteins, NAPVSIPQ (NAP) and SALLRSIPA
(SAL), mimic the activity of their parent proteins. These peptides
have been shown to exert a protective eﬀect against oxidative
stress, the severity of traumatic head injury, stroke, and toxicity
associated with the Aβ peptide, and to stabilize and repair
microtubules (Gozes et al., 2005, 2008). A preliminary study
showed that prenatal treatment (in the period E8–E12) with
NAP+SAL prevents the delay of neurodevelopmental milestones
in trisomic oﬀspring (Toso et al., 2008). At a cellular level,
prenatal NAP+SAL restore altered subunits of the NMDA
receptor and GABAA receptor (Vink et al., 2009), suggesting
that one mechanism by which treatment exerts its eﬀect may
be the normalization of the eﬃcacy of excitatory and inhibitory
pathways. In a subsequent study the eﬀect of prenatal treatment
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(in the period E8–E12) with NAP+SAL on learning and memory
was examined when the oﬀspring had reached 8–10 months
of age (Incerti et al., 2012). Prenatally-treated Ts65Dn mice
exhibited a learning curve that was similar to that of untreated
euploid mice. Unfortunately, the results of the probe test are
not mentioned and thus it is not possible to establish the eﬀect
of this treatment on memory. Moreover, the study did not
examine the eﬀects of treatment on neurogenesis and overall
brain development. However, the results prospect the possibility
of potential pregnancy interventions for DS with these peptides.
SGS-111
Neurons of DS patients exhibit a three- to four-fold increase
in intracellular reactive oxygen species (ROS) due to over
expression of SOD1, the gene that is responsible for the
formation of the enzyme superoxide dismutase that changes
oxygen free radicals into hydrogen peroxide. This oxidative
stress, which damages mithocondrial membrane and lipids,
occurs in DS during pre- and post-natal development and
can modify critical processes of neurogenesis, diﬀerentiation,
migration, and survival. Therefore, oxidative stress has been
linked to the brain abnormalities observed in DS. Since oxidative
stress has been reported as early as in the fetal stage, SGS-
111, an analog of piracetam with neuroprotective and nootropic
properties, was administered to pregnant Ts65Dn females from
the day of conception, throughout pregnancy, and to their
pups during the following 5 months (Rueda et al., 2008b). The
behavioral characterization carried out at the end of treatment
showed that chronic administration of the antioxidant SGS-111
reduced the hyperactivity shown by Ts65Dn mice but failed to
improve learning and memory. The lack of eﬀects may be due
to the fact that in Ts65Dn mice the MWM task is relatively
independent of the neurotoxic eﬀect of increased oxidative stress.
Tocopherol
Another important aspect of oxidative stress found in DS brains
is lipid damage caused by elevated levels of lipid peroxidation.
It has been reported that the concentration of isoprostanes (a
marker for lipid peroxidation) in the amniotic ﬂuid of mothers
who were pregnant with DS fetuses was nine times greater than
in pregnancies involving normal fetuses, suggesting that lipid
peroxidation occurs early in pregnancy (Perrone et al., 2007).
Therefore, the antioxidant α-tocopherol, the most biologically
active form of vitamin E, was chronically administered to
pregnant Ts65Dn females from the day of conception throughout
the pregnancy and to their pups until adulthood, in order to
prevent the developmental consequences of elevated oxidative
stress (Shichiri et al., 2011). Supplementation of α-tocopherol
was found to reduce acroleine, a lipid peroxidation product,
in the dentate gyrus of adult Ts65Dn mice and this eﬀect
was accompanied by an increase in granule cell density. In
addition, treatment ameliorated abnormal anxiety/regardlessness
in the Elevated-Plus Maze task in Ts65Dn mice, improved spatial
learning, and partially improved retention memory in the MWM
test. No eﬀect of treatment on hyperactivity was found in the
spontaneous motor activity test.
EGCG
Although this review is focused on therapies in the Ts65Dn
mouse model, we will brieﬂy report data obtained in the
transgenic YACtg152F7 mouse, a strain that over expresses
DYRK1A kinase, in view of the potential impact for DS.
Transgenic YACtg152F7 mice were treated with two diﬀerent
polyphenol-based diets, from gestation to adulthood (Guedj
et al., 2009). Chronic administration of polyphenols from
green tea (that include EGCG) was found to correct, in adult
transgenic mice, brain weight, and thalamus-hypothalamus
volume alterations that are strongly related to Dyrk1a gene
copy number. Moreover, this treatment restored hippocampal
mRNA levels for the neurotrophic factor BDNF and its plasma
membrane receptor TrkB. Consistently with the positive eﬀect
of treatment on these markers of synaptic plasticity, long-term
memory, assessed using the Novel Object Recognition test, was
completely restored in treated transgenic mice.
Timing is All
The studies carried out in mouse models at adult life stages
show that it is possible to improve or even rescue hippocampal-
dependent learning and memory, although the duration of these
eﬀects still remains a matter of investigation in the majority of
cases. After the period of neuron proliferation and maturation,
which takes place in the prenatal and neonatal period, there
is no means to increase the number of neurons forming the
brain, except—to a limited extent—for the hippocampal dentate
gyrus. Thus, after the critical periods of neurogenesis and
synaptogenesis the brain can undergo relatively limited plastic
changes and late therapies are unlikely to exert drastic changes
in the brain. Yet, although late therapies may exert a limited
beneﬁt, even a partial improvement of ID in adults with DS
and/or prevention of AD development would be an extremely
important achievement. Importantly, the results reviewed above
clearly show that therapies administered during the early stages
of brain development have an extremely pronounced eﬀect on
the trisomic brain in terms of the phenotypic features that they
are able to rescue and in terms of the duration of their eﬀects. The
studies in DS mouse models provide proof of principle evidence
that it might be possible to rescue brain development provided
that treatments are administered during the earliest phases of
brain development. The magnitude and striking persistence of
the eﬀects of neonatal and prenatal interventions emphasizes the
importance of early treatment in DS.
The normal ontogeny of neural development in rodents
is diﬀerent from humans because rodents have considerable
post-natal development and humans have considerably more
prenatal maturation of their nervous systems (Figure 4).
This aspect is fundamental to the planning of a correct
pharmacological intervention during a speciﬁc phase of brain
development. In mice, cortical neurogenesis takes place between
embryonic days E11–E17 (Takahashi et al., 1996) (Figure 4A).
At birth, except for a few specialized regions, including the
subventricular zone/rostral migratory stream, the hippocampal
dentate gyrus and the cerebellar cortex, the brain enters a state
of replicative quiescence. In the hippocampal dentate gyrus,
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although neurogenesis begins at E10 it exhibits its maximum
rate in the ﬁrst two post-natal weeks and then continues at a
slow rate throughout life (Altman and Bayer, 1975, 1990a,b)
(Figure 4A). In the mouse cerebellum, granule cell production
begins at approximately E15 and is accomplished by the second
post-natal week (Sillitoe and Joyner, 2007; Sudarov and Joyner,
2007) (Figure 4A). In the human brain, after the formation of the
neural tube, (by gestational week 3), neural progenitors produce
neurons that migrate from the ventricular zone, the primitive
epithelial sheet of dividing neural progenitor cells, to their ﬁnal
destination in the regions that will form the diﬀerent brain parts.
In the human forebrain neocortical neurons are generated during
a restricted period that begins at approximately gestational week
6 and is largely completed by week 18 (Stiles and Jernigan,
2010) (Figure 4B). After their ﬁnal division, postmitotic neurons
migrate outward from the VZ and once they have reached their
target regions develop axons and dendrites and begin to form
synaptic connections. Synaptic production continues during the
ﬁrst two post-natal years (Figure 4B). In the human dentate
gyrus, neurogenesis begins at approximately gestational week
12 and is almost accomplished within the ﬁrst post-natal year
(Seress et al., 2001; Rice and Barone, 2010), although, similarly
to rodents, it continues at a slow rate throughout life (Eriksson
et al., 1998) (Figure 4B). Production of cerebellar granule cells
starts at gestational week 12 (ten Donkelaar et al., 2003) and
continues in the ﬁrst few post-natal months (Abráham et al.,
2001) (Figure 4B). Noninvasive prenatal testing (NIPT) for DS,
using massively parallel sequencing of maternal plasma DNA,
facilitates early detection of aﬀected fetuses. As envisaged by
Guedj et al., if NIPT is performed at approximately 12 weeks of
pregnancy there is a potential 28-week window of opportunity
in which to treat the fetus by orally administering small
molecules to the mother (Guedj and Bianchi, 2013; Guedj et al.,
2014). Considering the timeline of brain development, treatment
during weeks 12–16 of pregnancy may have a large impact on
cortical neurogenesis (Figure 4B). Treatments after week 16 may
principally modulate cortical neuron maturation and synapse
formation. Finally, treatment during late pregnancy and the
ﬁrst years of life may have a large impact on neurogenesis in
the hippocampal dentate gyrus and cerebellum. Demonstration,
obtained in mouse models, that the defects of the DS brain are
reversible opens a breakthrough for the prevention of intellectual
disability. The timeline of human brain development (Figure 4B)
shows that there are windows of opportunity that can be
exploited in order to pharmacologically improve (and hopefully,
rescue) the neurodevelopmental alterations that characterize the
DS brain.
Translational Impact of Studies in Mouse
Models
The discovery that early pharmacotherapies can restore brain
development in mouse models of DS raises the question of
the translation of these results to human beings with DS.
When designing prenatal or neonatal treatments for DS two
important issues must be taken into account: the placental (and
blood-brain) barrier and the possible toxicity of treatment. The
drugs used so far in mice cross the placental and brain barrier
but their use may pose some caveats in view of potential side
eﬀects. Pharmacological stimulation of the Shh pathway with
SAG in newborn infants as a therapeutic strategy might be
problematic. Since chronic Shh pathway stimulation is observed
in a number of tumor types, a better understanding of the
side eﬀects of Shh treatment is required. Fluoxetine, which is
an antidepressant prescribed in adults and adolescents, may
be safer than SAG. Although it is in clinical trial in children
as a treatment for various behavioral disturbances (Alcamí
Pertejo et al., 2000; DeLong et al., 2002; Hollander et al., 2005),
possible side eﬀects in neonates cannot be ruled out. Fluoxetine
use in early pregnancy has been associated with a slightly
increased risk of speciﬁc cardiovascular malformations (Reefhuis
et al., 2015). However, another recent study conducted on a
large cohort of subjects (approximately 36,700 exposed infants
and 2,200,000 unexposed infants) indicates that there is not a
substantial teratogenic eﬀect of SSRI, including ﬂuoxetine, during
the ﬁrst trimester of pregnancy (Furu et al., 2015). Exposure
to antidepressants (including ﬂuoxetine) during the second and
third trimester does not have substantial eﬀects on milestones
of development (Einarson et al., 2009; Pedersen et al., 2010).
However, the potential risk of pre-term birth (Hayes et al.,
2012) and pulmonary hypertension in the neonate (Chambers
et al., 2006; Olivier et al., 2013) cannot be ruled out. It must
also be observed that in utero exposure to serotonin reuptake
inhibitors may result in a neonatal withdrawal syndrome (Moses-
Kolko et al., 2005; Sanz et al., 2005). Though the withdrawal
eﬀect is generally self-limited, this aspect must be taken into
account. Considering the impressive eﬀects of ﬂuoxetine in a
mouse model of DS, the side eﬀects of prenatal exposure to
ﬂuoxetine may be considered a relatively minor problem in the
face of the possible rescue of cognitive disability. At present, there
are no published data on DS babies born from mothers taking
ﬂuoxetine (or other antidepressants). A pilot feasibility trial
of perinatal ﬂuoxetine treatment at the Southwestern Medical
Center of the University of Texas was approved in 2014 and its
start is scheduled for 2015 (Byerly, M., Carlin, M. and Horsager-
Boehrer, R., 2014. A Pilot Feasibility Trial of Prenatal and Early
Post-natal Fluoxetine Treatment for Intellectual Impairments of
Down Syndrome https://wwwutswmedicineorg/stories/articles/
year-2015/down-syndromehtml). EGCG is a phytochemical
derived from green tea extracts. The use and dosage of substances
that derive from plants as natural remedies for various diseases
is deeply rooted in the history of mankind. Therefore, natural
substances may represent attractive tools for the therapy of
various disturbances, including DS. EGCG appears to be a
safe phytochemical (Vacca and Valenti, 2015) and its use has
numerous beneﬁcial health eﬀects (Kim et al., 2014). EGCG
is often classiﬁed as an antioxidant but it may function as a
pro-oxidant in some cellular contexts. EGCG has many actions
that do not depend on anti-oxidant mechanisms, including
direct interaction with proteins and phospholipids in the plasma
membrane, and regulation of signal transduction pathways and
transcription factors (Kim et al., 2014). It has been shown that
high doses of EGCG have hepatotoxic eﬀects (Lambert et al.,
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2009). However, the doses used in pre-clinical studies in mouse
models (De la Torre et al., 2014; Stagni et al., 2014) and in
the clinical trials with EGCG (reported in Table 3) are well
below those that are known to cause adverse eﬀects. EGCG
administered to pregnant rats does not have teratogenic eﬀects
(Isbrucker et al., 2006). It is not known whether EGCG may
have adverse eﬀects during pregnancy in humans. A clinical trial
for young adults with DS (De la Torre et al., 2014) shows that
the positive eﬀect of treatment with EGCG on behavior tends
to disappear with time. We found that neonatal treatment with
EGCG rescued hippocampal development in the Ts65Dn mouse
model, similarly to that with ﬂuoxetine. At this point it is of
paramount importance to establish whether EGCG administered
prenatally can rescue overall brain development, similarly to
ﬂuoxetine, and whether this eﬀect is retained with time. If so,
EGCG may be a promising treatment for the prevention of ID
in DS. The neuroprotective peptides NAP and SAL can be orally
administered. Moreover, NAP penetrates cells and crosses the
blood-brain barrier after nasal or systemic administration. This
would make treatment of individuals with DS easily feasible.
These peptides do not seem to have adverse eﬀects in animal
models, and functional behavioral assays in rats show no adverse
side eﬀects with NAP concentrations that are approximately
500-fold higher than the biologically active dose (see Gozes
et al., 2008). The beneﬁcial eﬀects of embryonic treatment on
learning and memory in the Ts65Dn mouse model suggest
that these peptides may be employed for prenatal treatment
in DS. Choline and vitamin E are important supplements that
should be taken in adequate amounts, and choline in large
amounts appears to be required during pregnancy to support
fetal development (Yan et al., 2013). No toxic or teratogenic
eﬀects are reported in the literature following an intake of the
recommended daily range dosage of choline and vitamin E.
Thus, choline and vitamin E are not likely to cause adverse
eﬀects on fetuses or babies with DS. Embryonic treatment with
vitamin E improves spatial learning and delays the onset of
cognitive and morphological brain abnormalities in the Ts65Dn
mouse model (Shichiri et al., 2011). Although vitamin E may
represent a safe and eﬀective treatment during pregnancy, its
actions appear less prominent in comparison with those of
other agents. Therefore, it may be useful to combine other
treatments with vitamin E in order to obtain a more signiﬁcant
outcome. Embryonic/early post-natal choline supplementation
was found to restore behavior when mice were aged 13–17
months (Velazquez et al., 2013). Since choline is considered to be
a very safe nutrient, it may be used for prenatal treatment for DS.
However, further studies are needed in order to establish whether
choline restores the neurodevelopmental defects of the DS brain
in addition to preventing age-related cognitive deterioration.
No data are available regarding potential toxic eﬀects of SGS-
111 during pregnancy, and the eﬀects of early treatment with
SGS-111 are less prominent in comparison with those of other
agents.
Conclusion
The exciting discovery that the brain abnormalities of mouse
models of DS can be prevented with early interventions gives
us reason to believe that treatments during pregnancy may
rescue brain development in fetuses with DS. Importantly, three
reported cases of DS babies whose mothers took high doses
of vitamin B (plus other substances) during pregnancy provide
encouraging results (Baggot and Baggot, 2014) and strengthen
the idea that early therapies for DS may have a very positive
impact on ID. For this reason we deem it extremely important
to expedite the discovery of additional therapies practicable
in humans, in order to identify the best treatment/s in terms
of eﬃcacy and paucity of side eﬀects. Prompt achievement of
this goal is the big challenge for the scientiﬁc community of
researchers interested in DS.
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